Literature DB >> 9547670

IL-4R expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB389-IL-4).

J Cai1, T Zheng, J Murphy, C A Waters, G Y Lin, P S Gill.   

Abstract

Interleukin-4 (IL-4) is a pleiotropic cytokine affecting growth and differentiation of various cell types as well as regulating other cytokines. To study the effect of IL-4 on AIDS-related Kaposi's sarcoma (AIDS-KS) cells, we first examined the tumor cells for IL-4 receptor (IL-4R) expression. KS cells express a single 4 kB IL-4R-specific mRNA and 1828 +/- 408 high affinity IL-4 binding sites per cell with a dissociation constant (Kd) of 154 +/- 37 pM. Addition of recombinant human IL-4 (rIL-4) minimally inhibited AIDS-KS cell growth and expression of IL-6. We then studied the effects of a chimeric fusion toxin DAB389-IL-4 which exerts cellular toxicity only on cells expressing IL-4R. DAB389-IL-4 inhibited protein synthesis in AIDS-KS cells at low concentrations (IC50 of 5 x 10(-11) M). This effect was abrogated by neutralizing antibody to IL-4 (25D2). We conclude that KS cells express a functional IL-4R and this receptor could serve as a target for novel therapy with agents such as DAB389-IL-4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9547670     DOI: 10.1023/a:1005958123893

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  28 in total

1.  Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin.

Authors:  R K Puri; M Ogata; P Leland; G M Feldman; D FitzGerald; I Pastan
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

2.  The crystal structure of diphtheria toxin.

Authors:  S Choe; M J Bennett; G Fujii; P M Curmi; K A Kantardjieff; R J Collier; D Eisenberg
Journal:  Nature       Date:  1992-05-21       Impact factor: 49.962

3.  Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells.

Authors:  S Nakamura; S Z Salahuddin; P Biberfeld; B Ensoli; P D Markham; F Wong-Staal; R C Gallo
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

4.  Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.

Authors:  J P Shaw; D E Akiyoshi; D A Arrigo; A E Rhoad; B Sullivan; J Thomas; F S Genbauffe; P Bacha; J C Nichols
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

5.  Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells.

Authors:  J D Lee; S G Swisher; E H Minehart; W H McBride; J S Economou
Journal:  J Leukoc Biol       Date:  1990-05       Impact factor: 4.962

6.  Interleukin-4 receptor expression by human B cells: functional analysis with a human interleukin-4 toxin, DAB389IL-4.

Authors:  H H Jabara; D Vercelli; L C Schneider; D P Williams; F S Genbauffe; L R Poisson; C A Waters; R S Geha
Journal:  J Allergy Clin Immunol       Date:  1995-04       Impact factor: 10.793

7.  Cloned fragment of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry.

Authors:  M Colombatti; L Greenfield; R J Youle
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

8.  Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma.

Authors:  Y Kawakami; S A Rosenberg; M T Lotze
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

9.  Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin.

Authors:  W Debinski; R K Puri; I Pastan
Journal:  Int J Cancer       Date:  1994-09-01       Impact factor: 7.316

10.  A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin.

Authors:  W Debinski; R K Puri; R J Kreitman; I Pastan
Journal:  J Biol Chem       Date:  1993-07-05       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.